NeuroPace (NPCE) Competitors $7.80 +0.81 (+11.59%) (As of 11/6/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NPCE vs. UTMD, SMTI, TELA, CVRX, XAIR, KIDS, IRMD, AXGN, SIBN, and FNAShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Utah Medical Products (UTMD), Sanara MedTech (SMTI), TELA Bio (TELA), CVRx (CVRX), Beyond Air (XAIR), OrthoPediatrics (KIDS), Iradimed (IRMD), AxoGen (AXGN), SI-BONE (SIBN), and Paragon 28 (FNA). These companies are all part of the "medical" sector. NeuroPace vs. Utah Medical Products Sanara MedTech TELA Bio CVRx Beyond Air OrthoPediatrics Iradimed AxoGen SI-BONE Paragon 28 Utah Medical Products (NASDAQ:UTMD) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Does the MarketBeat Community believe in UTMD or NPCE? Utah Medical Products received 127 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 61.45% of users gave Utah Medical Products an outperform vote while only 56.52% of users gave NeuroPace an outperform vote. CompanyUnderperformOutperformUtah Medical ProductsOutperform Votes15361.45% Underperform Votes9638.55% NeuroPaceOutperform Votes2656.52% Underperform Votes2043.48% Which has preferable earnings and valuation, UTMD or NPCE? Utah Medical Products has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUtah Medical Products$50.22M4.65$16.64M$4.2715.73NeuroPace$65.42M3.48-$32.96M-$1.09-7.16 Is UTMD or NPCE more profitable? Utah Medical Products has a net margin of 34.62% compared to NeuroPace's net margin of -41.63%. Utah Medical Products' return on equity of 12.04% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Utah Medical Products34.62% 12.04% 11.42% NeuroPace -41.63%-195.26%-29.88% Do insiders & institutionals believe in UTMD or NPCE? 69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 6.6% of Utah Medical Products shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, UTMD or NPCE? Utah Medical Products has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Does the media prefer UTMD or NPCE? In the previous week, Utah Medical Products had 1 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Utah Medical Products and 4 mentions for NeuroPace. Utah Medical Products' average media sentiment score of 0.74 beat NeuroPace's score of 0.46 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate UTMD or NPCE? NeuroPace has a consensus target price of $15.00, suggesting a potential upside of 92.31%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Utah Medical Products.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeuroPace 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryUtah Medical Products beats NeuroPace on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.76M$4.43B$5.30B$8.76BDividend YieldN/A42.37%5.19%4.03%P/E Ratio-7.1628.19101.4416.55Price / Sales3.4863.30677.09104.43Price / CashN/A49.9235.0731.67Price / Book9.874.734.735.23Net Income-$32.96M$12.14M$115.11M$224.13M7 Day Performance20.93%5.34%3.29%3.73%1 Month Performance16.77%8.65%9.13%6.93%1 Year Performance10.33%46.00%37.82%27.75% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.3674 of 5 stars$7.80+11.6%$15.00+92.3%+8.3%$227.76M$65.42M-7.16170Upcoming EarningsUTMDUtah Medical Products3.9573 of 5 stars$64.64+0.9%N/A-16.1%$224.95M$50.22M15.14180News CoverageSMTISanara MedTech2.1355 of 5 stars$33.45-0.2%N/A+31.4%$292.69M$64.99M-42.8860Upcoming EarningsTELATELA Bio3.1199 of 5 stars$2.85-1.7%N/A-45.9%$70.44M$64.74M-1.66120Gap UpCVRXCVRx1.9113 of 5 stars$15.05+12.3%N/A-9.1%$327.88M$47.26M-5.57200Analyst ForecastHigh Trading VolumeXAIRBeyond Air4.6422 of 5 stars$0.48-2.0%N/A-77.0%$22.66M$1.16M-0.2970Upcoming EarningsKIDSOrthoPediatrics4.495 of 5 stars$28.74+5.0%N/A+12.9%$695.80M$148.73M-26.37200News CoverageGap UpIRMDIradimed4.7232 of 5 stars$49.36+2.2%N/A+32.4%$625.39M$65.56M33.81110Dividend AnnouncementGap UpAXGNAxoGen1.0381 of 5 stars$14.20+1.8%N/A+290.1%$622.39M$159.01M-37.37426Upcoming EarningsGap UpSIBNSI-BONE4.1924 of 5 stars$13.63+1.0%N/A-8.2%$568.24M$138.89M-13.50350Upcoming EarningsGap UpFNAParagon 282.4331 of 5 stars$6.06+7.8%N/A-26.8%$506.27M$235.44M-8.78343,000Upcoming EarningsGap Up Related Companies and Tools Related Companies Utah Medical Products Alternatives Sanara MedTech Alternatives TELA Bio Alternatives CVRx Alternatives Beyond Air Alternatives OrthoPediatrics Alternatives Iradimed Alternatives AxoGen Alternatives SI-BONE Alternatives Paragon 28 Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NPCE) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.